Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Investigating the Nutritional and Recovery Habits of Tennis Players.

Fleming JA, Naughton RJ, Harper LD.

Nutrients. 2018 Apr 3;10(4). pii: E443. doi: 10.3390/nu10040443.

2.

Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis.

Coelho T, Merlini G, Bulawa CE, Fleming JA, Judge DP, Kelly JW, Maurer MS, Planté-Bordeneuve V, Labaudinière R, Mundayat R, Riley S, Lombardo I, Huertas P.

Neurol Ther. 2016 Jun;5(1):1-25. doi: 10.1007/s40120-016-0040-x. Epub 2016 Feb 19. Review.

3.

Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.

Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA, Packman J, Powers ET, Wiseman RL, Foss TR, Wilson IA, Kelly JW, Labaudinière R.

Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9629-34. doi: 10.1073/pnas.1121005109. Epub 2012 May 29.

4.

Systematic exploration of essential yeast gene function with temperature-sensitive mutants.

Li Z, Vizeacoumar FJ, Bahr S, Li J, Warringer J, Vizeacoumar FS, Min R, Vandersluis B, Bellay J, Devit M, Fleming JA, Stephens A, Haase J, Lin ZY, Baryshnikova A, Lu H, Yan Z, Jin K, Barker S, Datti A, Giaever G, Nislow C, Bulawa C, Myers CL, Costanzo M, Gingras AC, Zhang Z, Blomberg A, Bloom K, Andrews B, Boone C.

Nat Biotechnol. 2011 Apr;29(4):361-7. doi: 10.1038/nbt.1832. Epub 2011 Mar 27.

5.

Biological characterization of MLN944: a potent DNA binding agent.

Sappal DS, McClendon AK, Fleming JA, Thoroddsen V, Connolly K, Reimer C, Blackman RK, Bulawa CE, Osheroff N, Charlton P, Rudolph-Owen LA.

Mol Cancer Ther. 2004 Jan;3(1):47-58.

6.

Complementary whole-genome technologies reveal the cellular response to proteasome inhibition by PS-341.

Fleming JA, Lightcap ES, Sadis S, Thoroddsen V, Bulawa CE, Blackman RK.

Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1461-6.

Supplemental Content

Loading ...
Support Center